US Biopharmaceutical Company Liminatus Pharma Plans to Raise $500 Million to Invest in BNB
BlockBeats News, July 28th, According to a report by businessinsider, Clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) today announced plans to strategically expand into the cryptocurrency and blockchain space.
The company plans to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management plan. Through this platform, Liminatus plans to gradually raise and deploy up to $500 million in funds, with the goal of strategically long-term investing in BNB.
Liminatus emphasized that while the company remains fully committed to its core business - advancing cancer treatments and pancreatic cancer diagnostic technologies, expanding into the digital asset space is seen as a necessary step to support long-term growth and enhance shareholder value.
Liminatus is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer patients. The company is advancing a series of novel therapies targeting cancer antigens and tumor-specific immune responses.
You may also like
Gainers
Latest Crypto News
Bastion announces providing Sony Bank with stablecoin issuance, reserve management, and custody services
The UK government is considering banning cryptocurrency for political donations to avoid foreign interference
Federal Reserve Governor Bowman: Seeking to Establish New Rules for Banks and Stablecoins to Ensure Fair Competition
Sahara Official Denies "Token's Sharp Decline Due to Market Maker Liquidation"
Unlimit Launches Stablecoin Decentralized Clearing Platform Stable.com
Customer Support:@weikecs
Business Cooperation:@weikecs
Quant Trading & MM:bd@weex.com
VIP Services:support@weex.com